In the EBMT-95 cohort the frequencies of allogeneic SCT patients showing GVL responses after DLT increased with the severity of GVHD. While 75% of patients with grade I GVHD showed tumor regression, this increased to 85% in patients with GVHD of grade II or greater. Nevertheless, 50% of patients showing no clinical signs of GVHD also showed complete tumor remissions following DLT.